BioMarin Pharmaceutical leadership stated on August 13, 2025, that the company is experiencing robust demand for its key therapies and noted an increase in net new U.S. patients.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioMarin Pharmaceutical leadership stated on August 13, 2025, that the company is experiencing robust demand for its key therapies and noted an increase in net new U.S. patients.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BioMarin Pharmaceutical
American company
Related events
Coverage
Newest first; wire copies grouped- StockStoryBMRN Q2 Deep Dive: Pipeline Advances and Strategic Expansion Drive Upbeat Results Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results topping the market’s revenue expecta